Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 8/20 | 0.54 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.40 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.35 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437078 | 0.86 | MDM2 (0.63) | MDM2TRPV3SLC16A3SLC16A1NOTUM | |
| SCHEMBL1437076 | 0.86 | MDM2 (0.75) | MDM2TRPV3SLC16A3SLC16A1NOTUM | |
| SCHEMBL9894084 | 0.85 | MDM2 (0.72) | MDM2TRPV3NOTUM | |
| SCHEMBL9893966 | 0.83 | MDM2 (0.59) | MDM2SLC16A3SLC16A1 | |
| SCHEMBL9893644 | 0.82 | MDM2 (0.60) | MDM2TRPV3 | |
| SCHEMBL1437365 | 0.80 | MDM2 (0.74) | MDM2TRPV3NOTUMHSD11B1 | |
| SCHEMBL28796359 | 0.80 | MDM2 (0.53) | MDM2TRPV3SLC16A3SLC16A1NOTUM | |
| SCHEMBL1437209 | 0.77 | MDM2 (0.58) | MDM2HSD11B1 | |
| SCHEMBL9893622 | 0.72 | MDM2 (0.66) | MDM2 | |
| SCHEMBL1437606 | 0.72 | MDM2 (0.54) | MDM2TRPV3OPRL1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102574785-A | Tetra-substituted heteroaryl compounds and their use as MDM2 and/or MDM4 modulators | NOVARTIS AG | 2012-07-11 | — | — | CN | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885TRPV3 4410/4885SLC16A3 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.